Open AccessAfatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment
Author(s) -
Rebecca Edwards,
Christine Andan,
Rajesh V. Lalla,
Mario E. Lacouture,
Dennis E. O'Brien,
Lecia V. Sequist
Publication year - 2018
Publication title -
clinical journal of oncology nursing
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.375
H-Index - 43
eISSN - 1538-067X
pISSN - 1092-1095
DOI - 10.1188/18.cjon.542-548
Subject(s) - afatinib , medicine , tolerability , adverse effect , oncology , lung cancer , epidermal growth factor receptor , clinical trial , intensive care medicine , cancer , erlotinib
Afatinib is an oral, irreversible ErbB family blocker indicated for first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with non-resistant epidermal growth factor receptor (EGFR) mutations. Afatinib is also approved for the treatment of metastatic squamous NSCLC following progression on platinum-based chemotherapy. Common afatinib-associated toxicities include gastrointestinal and dermatologic events, which can be dose limiting.